Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2Glioblastoma 2Triple Negative Breast Neoplasms 1Gliosarcoma 1Glioma 1Breast Neoplasms 1Astrocytoma 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Gemcitabine 19130-nm albumin-bound paclitaxel 16Specimen Handling 15Irinotecan 11Magnetic Resonance Spectroscopy 10Fluorouracil 10Leucovorin 9Biopsy 9Oxaliplatin 8pembrolizumab 7Cyclophosphamide 7fludarabine 6Cisplatin 5Pemetrexed 4Cetuximab 4Albumin-Bound Paclitaxel 4zimberelimab 3trastuzumab deruxtecan 3olaparib 3irinotecan sucrosofate 3durvalumab 3dehydroftorafur 3aldesleukin 3Taxes 3Radiosurgery 3Nivolumab 3Immunoglobulin G 3Disulfides 3Carboplatin 3veliparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × veliparib × 30 days × Clear all
NCT01585805 2026-06-02

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
83 enrolled 23 charts
Gastrointestinal

Pancreatic Neoplasms

NCT02890355 2026-05-20

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
123 enrolled 15 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡